Keros Therapeutics (KROS) EBITDA (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of EBITDA data on file, last reported at -$29.3 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA rose 45.04% year-over-year to -$29.3 million; the trailing twelve-month figure through Dec 2025 stood at $67.6 million (up 132.05% YoY), and the FY2025 full-year result was $67.6 million, up 132.05% from the prior year.
• EBITDA for Q4 2025 stood at -$29.3 million, down from -$15.4 million in the prior quarter.
• Across five years, EBITDA topped out at $152.0 million in Q1 2025 and bottomed at -$58.7 million in Q3 2024.
• The 5-year median for EBITDA is -$31.3 million (2022), against an average of -$24.2 million.
• The widest annual swing landed in 2022, when EBITDA tumbled 556.8%; it then surged 413.59% in 2025.
• A 5-year view of EBITDA shows it stood at -$4.9 million in 2021, then sank by 556.8% to -$32.0 million in 2022, then sank by 45.35% to -$46.5 million in 2023, then decreased by 14.64% to -$53.3 million in 2024, then jumped by 45.04% to -$29.3 million in 2025.
• The last three EBITDA figures came in at -$29.3 million (Q4 2025), -$15.4 million (Q3 2025), and -$39.8 million (Q2 2025), per Business Quant data.

Peer Comparison